Gracell Biotechnologies Inc (GRCL)

NASDAQ

$10.25

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China.

Website: https://www.gracellbio.com

Sector:

Healthcare

Industry:

Biotechnology

Target: $10.58 (+3.22%)

Market Cap

$990M

Price Chart

Adjust inflation

Log

Valuation

Market Cap$990M

P/S732.21

P/B4.39

Profitability

Gross Profit (TTM)$366K

EBITDA-$510M

EPS-$0.97

Growth & Risk

Sharpe Ratio1.34